SK284590B6 - Suspenzia ziprasidonu - Google Patents

Suspenzia ziprasidonu Download PDF

Info

Publication number: SK284590B6
Authority: SK; Slovakia
Prior art keywords: ziprasidone; suspension; polysorbate; amount; acid addition
Prior art date: 1999-05-27

Application number

SK1678-2001A

Other languages

English (en)

Slovak (sk)

Other versions

SK16782001A3 (sk

Inventor

Daniel Ray Arenson

Hong Qi

Original Assignee

Pfizer Products Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-27

Filing date

2000-05-08

Publication date

2005-07-01

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22472103&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284590(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-08 Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.

2002-09-10 Publication of SK16782001A3 publication Critical patent/SK16782001A3/sk

2005-07-01 Publication of SK284590B6 publication Critical patent/SK284590B6/sk

Links

239000000725 suspension Substances 0.000 title claims abstract description 49
MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title claims abstract description 42
229960000607 ziprasidone Drugs 0.000 title claims abstract description 40
150000003839 salts Chemical class 0.000 claims abstract description 28
239000003795 chemical substances by application Substances 0.000 claims abstract description 23
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 22
229920000136 polysorbate Polymers 0.000 claims abstract description 22
239000002253 acid Substances 0.000 claims abstract description 20
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 20
229950008882 polysorbate Drugs 0.000 claims abstract description 19
239000012458 free base Substances 0.000 claims abstract description 14
229940075614 colloidal silicon dioxide Drugs 0.000 claims abstract description 6
ZCBZSCBNOOIHFP-UHFFFAOYSA-N ziprasidone hydrochloride hydrate Chemical group [H+].O.[Cl-].C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 ZCBZSCBNOOIHFP-UHFFFAOYSA-N 0.000 claims description 21
229960003474 ziprasidone hydrochloride Drugs 0.000 claims description 16
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims description 9
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 9
229940068968 polysorbate 80 Drugs 0.000 claims description 9
229920000053 polysorbate 80 Polymers 0.000 claims description 9
235000019640 taste Nutrition 0.000 claims description 6
229910001514 alkali metal chloride Inorganic materials 0.000 claims description 5
229910001617 alkaline earth metal chloride Inorganic materials 0.000 claims description 4
229920001213 Polysorbate 20 Polymers 0.000 claims description 3
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims description 3
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 3
229940068977 polysorbate 20 Drugs 0.000 claims description 3
239000000203 mixture Substances 0.000 description 18
239000008119 colloidal silica Substances 0.000 description 14
239000002245 particle Substances 0.000 description 13
239000000796 flavoring agent Substances 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
239000004615 ingredient Substances 0.000 description 10
235000013355 food flavoring agent Nutrition 0.000 description 9
238000004062 sedimentation Methods 0.000 description 9
238000002156 mixing Methods 0.000 description 8
150000001875 compounds Chemical class 0.000 description 7
238000009472 formulation Methods 0.000 description 7
238000000034 method Methods 0.000 description 7
238000009736 wetting Methods 0.000 description 7
239000006260 foam Substances 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
238000003756 stirring Methods 0.000 description 5
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 4
239000012736 aqueous medium Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
235000019658 bitter taste Nutrition 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000003814 drug Substances 0.000 description 4
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
239000003921 oil Substances 0.000 description 4
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 4
235000019333 sodium laurylsulphate Nutrition 0.000 description 4
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
-1 fatty acid esters Chemical class 0.000 description 3
235000003599 food sweetener Nutrition 0.000 description 3
239000001863 hydroxypropyl cellulose Substances 0.000 description 3
235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
229940068965 polysorbates Drugs 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
239000010670 sage oil Substances 0.000 description 3
239000007787 solid Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
239000003765 sweetening agent Substances 0.000 description 3
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
239000004034 viscosity adjusting agent Substances 0.000 description 3
241000167854 Bourreria succulenta Species 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
235000005979 Citrus limon Nutrition 0.000 description 2
244000131522 Citrus pyriformis Species 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
239000007900 aqueous suspension Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000019693 cherries Nutrition 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
235000013399 edible fruits Nutrition 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
238000005187 foaming Methods 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
238000000265 homogenisation Methods 0.000 description 2
230000001965 increasing effect Effects 0.000 description 2
229910001629 magnesium chloride Inorganic materials 0.000 description 2
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
239000001103 potassium chloride Substances 0.000 description 2
235000011164 potassium chloride Nutrition 0.000 description 2
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 2
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 2
229960003415 propylparaben Drugs 0.000 description 2
239000013049 sediment Substances 0.000 description 2
239000002002 slurry Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
239000004094 surface-active agent Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000000341 volatile oil Substances 0.000 description 2
239000000230 xanthan gum Substances 0.000 description 2
235000010493 xanthan gum Nutrition 0.000 description 2
229920001285 xanthan gum Polymers 0.000 description 2
229940082509 xanthan gum Drugs 0.000 description 2
244000099147 Ananas comosus Species 0.000 description 1
235000007119 Ananas comosus Nutrition 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
241000207199 Citrus Species 0.000 description 1
240000000560 Citrus x paradisi Species 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
240000009088 Fragaria x ananassa Species 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
235000017858 Laurus nobilis Nutrition 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
229920000161 Locust bean gum Polymers 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
244000070406 Malus silvestris Species 0.000 description 1
240000005561 Musa balbisiana Species 0.000 description 1
229920001214 Polysorbate 60 Polymers 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
240000005809 Prunus persica Species 0.000 description 1
235000006040 Prunus persica var persica Nutrition 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
241000220324 Pyrus Species 0.000 description 1
240000007651 Rubus glaucus Species 0.000 description 1
244000125380 Terminalia tomentosa Species 0.000 description 1
235000005212 Terminalia tomentosa Nutrition 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
235000009499 Vanilla fragrans Nutrition 0.000 description 1
244000263375 Vanilla tahitensis Species 0.000 description 1
235000012036 Vanilla tahitensis Nutrition 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
238000013019 agitation Methods 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
239000010617 anise oil Substances 0.000 description 1
230000000561 anti-psychotic effect Effects 0.000 description 1
230000002421 anti-septic effect Effects 0.000 description 1
235000021016 apples Nutrition 0.000 description 1
239000010692 aromatic oil Substances 0.000 description 1
235000021015 bananas Nutrition 0.000 description 1
239000002585 base Substances 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
229940092714 benzenesulfonic acid Drugs 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
229940119201 cedar leaf oil Drugs 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
239000010630 cinnamon oil Substances 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
239000010634 clove oil Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000008021 deposition Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229940088679 drug related substance Drugs 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
239000010642 eucalyptus oil Substances 0.000 description 1
229940044949 eucalyptus oil Drugs 0.000 description 1
239000000284 extract Substances 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
239000000416 hydrocolloid Substances 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
238000007689 inspection Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
235000010420 locust bean gum Nutrition 0.000 description 1
239000000711 locust bean gum Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
239000001627 myristica fragrans houtt. fruit oil Substances 0.000 description 1
239000003176 neuroleptic agent Substances 0.000 description 1
230000000701 neuroleptic effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
235000021017 pears Nutrition 0.000 description 1
230000035699 permeability Effects 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
239000007971 pharmaceutical suspension Substances 0.000 description 1
238000000053 physical method Methods 0.000 description 1
235000021018 plums Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
235000021013 raspberries Nutrition 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
238000005245 sintering Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
229960000999 sodium citrate dihydrate Drugs 0.000 description 1
238000003860 storage Methods 0.000 description 1
235000021012 strawberries Nutrition 0.000 description 1
IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid group Chemical class S(N)(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
150000003460 sulfonic acids Chemical class 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000001789 thuja occidentalis l. leaf oil Substances 0.000 description 1
239000010678 thyme oil Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
238000011179 visual inspection Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Organic Chemistry (AREA)
Psychiatry (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Colloid Chemistry (AREA)
Cosmetics (AREA)
General Preparation And Processing Of Foods (AREA)
Chemical Or Physical Treatment Of Fibers (AREA)
Diaphragms For Electromechanical Transducers (AREA)
Dental Preparations (AREA)

SK1678-2001A 1999-05-27 2000-05-08 Suspenzia ziprasidonu SK284590B6 (sk)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13626899P	1999-05-27	1999-05-27
PCT/IB2000/000593 WO2000072847A1 (fr)	1999-05-27	2000-05-08	Suspension de ziprasidone

Publications (2)

Publication Number	Publication Date
SK16782001A3 SK16782001A3 (sk)	2002-09-10
SK284590B6 true SK284590B6 (sk)	2005-07-01

Family

ID=22472103

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK1678-2001A SK284590B6 (sk)	1999-05-27	2000-05-08	Suspenzia ziprasidonu

Country Status (50)

Country	Link
EP (1)	EP1181018B1 (fr)
JP (1)	JP3942827B2 (fr)
KR (1)	KR100477782B1 (fr)
CN (1)	CN1196486C (fr)
AP (1)	AP1409A (fr)
AR (1)	AR022643A1 (fr)
AT (1)	ATE234097T1 (fr)
AU (1)	AU777413B2 (fr)
BG (1)	BG65367B1 (fr)
BR (1)	BR0010990A (fr)
CA (1)	CA2371550C (fr)
CO (1)	CO5170458A1 (fr)
CR (1)	CR6506A (fr)
CU (1)	CU23223B7 (fr)
CZ (1)	CZ20014230A3 (fr)
DE (1)	DE60001649T2 (fr)
DK (1)	DK1181018T3 (fr)
DZ (1)	DZ3049A1 (fr)
EA (1)	EA003907B1 (fr)
EE (1)	EE04704B1 (fr)
ES (1)	ES2191618T3 (fr)
GC (1)	GC0000190A (fr)
GE (1)	GEP20033113B (fr)
GT (1)	GT200000081A (fr)
HK (1)	HK1046366B (fr)
HN (1)	HN2000000071A (fr)
HR (1)	HRP20010878B1 (fr)
HU (1)	HUP0201297A3 (fr)
IL (2)	IL145950A0 (fr)
IS (1)	IS2396B (fr)
MA (1)	MA26741A1 (fr)
MX (1)	MXPA01012124A (fr)
MY (1)	MY127891A (fr)
NO (1)	NO320296B1 (fr)
NZ (1)	NZ514764A (fr)
OA (1)	OA11946A (fr)
PA (1)	PA8495801A1 (fr)
PE (1)	PE20010127A1 (fr)
PL (1)	PL196867B1 (fr)
RS (1)	RS50089B (fr)
SI (1)	SI1181018T1 (fr)
SK (1)	SK284590B6 (fr)
SV (1)	SV2001000085A (fr)
TN (1)	TNSN00112A1 (fr)
TR (1)	TR200103392T2 (fr)
TW (1)	TWI263498B (fr)
UA (1)	UA59491C2 (fr)
UY (1)	UY26166A1 (fr)
WO (1)	WO2000072847A1 (fr)
ZA (1)	ZA200109692B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7175855B1 (en)	1999-05-27	2007-02-13	Pfizer Inc.	Ziprasidone suspension
US10179130B2 (en)	1999-10-29	2019-01-15	Purdue Pharma L.P.	Controlled release hydrocodone formulations
KR100889069B1 (ko)	1999-10-29	2009-03-17	유로-셀티크 소시에떼 아노뉨	서방성 하이드로코돈 제형
BR0115382A (pt)	2000-10-30	2003-09-16	Euro Celtique Sa	Formulações para liberação controlada de hidrocodona, método de produzir analgesia efetiva, processo de preparação de uma forma farmacêutica de um sólido oral de liberação controlada, liberação controlada da forma farmacêutica oral e uso da forma farmacêutica
CN100337630C (zh) *	2002-03-12	2007-09-19	布里斯托尔-迈尔斯斯奎布公司	可口的口服悬浮液及其制备方法
AU2003267763A1 (en) *	2002-10-25	2004-05-13	Pfizer Products Inc.	Depot formulations of arylheterocyclic active agents in the form of a suspension
JP2006514923A (ja) *	2002-10-25	2006-05-18	ファイザー・プロダクツ・インク	注射可能な新規なデポ製剤
MXPA03009945A (es)	2002-11-05	2007-04-16	Lg Electronics Inc	Montaje para montar una pantalla de toque para un monitor con pantalla de cristal liquido.
US7667037B2 (en)	2003-10-24	2010-02-23	Teva Pharmaceutical Industries Ltd.	Processes for preparation of ziprasidone
WO2005107719A2 (fr)	2004-05-06	2005-11-17	Sandoz Ag	Composition pharmaceutique comprenant un medicament hydrophobe a solubilite amelioree
WO2005123086A2 (fr) *	2004-06-11	2005-12-29	Dr. Reddy's Laboratories Ltd.	Forme de dosage de ziprasidone
US20080268034A1 (en) *	2005-01-07	2008-10-30	Girish Karanth	Solid Oral Dosage Forms of Ziprasidone Containing Colloidal Silicone Dioxide
EP1901722A4 (fr) *	2005-06-20	2011-06-15	Elan Pharma Int Ltd	Compositions de nanoparticules à libération contrôlée comprenant des composés d'aryle hétérocyclique
US9198862B2 (en)	2005-07-22	2015-12-01	Rubicon Research Private Limited	Dispersible tablet composition
CN100391458C (zh) *	2006-02-07	2008-06-04	上海医药工业研究院	齐拉西酮或其盐包合物制备方法
KR20080076667A (ko) *	2007-02-15	2008-08-20	주식회사 중외제약	요변성 약학 조성물
JP4336380B1 (ja) *	2008-11-06	2009-09-30	塩野義製薬株式会社	水懸濁性を向上させた細粒剤
JP6272730B2 (ja) *	2014-05-21	2018-01-31	救急薬品工業株式会社	速溶性フィルム剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4831031A (en) *	1988-01-22	1989-05-16	Pfizer Inc.	Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5312925A (en) *	1992-09-01	1994-05-17	Pfizer Inc.	Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
US6150366A (en) *	1998-06-15	2000-11-21	Pfizer Inc.	Ziprasidone formulations

2000
- 2000-05-08 EA EA200101131A patent/EA003907B1/ru not_active IP Right Cessation
- 2000-05-08 AP APAP/P/2001/002346A patent/AP1409A/en active
- 2000-05-08 CN CNB008081204A patent/CN1196486C/zh not_active Expired - Fee Related
- 2000-05-08 NZ NZ514764A patent/NZ514764A/en unknown
- 2000-05-08 ES ES00920981T patent/ES2191618T3/es not_active Expired - Lifetime
- 2000-05-08 WO PCT/IB2000/000593 patent/WO2000072847A1/fr not_active Ceased
- 2000-05-08 EE EEP200100633A patent/EE04704B1/xx not_active IP Right Cessation
- 2000-05-08 CA CA002371550A patent/CA2371550C/fr not_active Expired - Lifetime
- 2000-05-08 BR BR0010990-8A patent/BR0010990A/pt not_active Application Discontinuation
- 2000-05-08 RS YUP-767/01A patent/RS50089B/sr unknown
- 2000-05-08 PL PL352826A patent/PL196867B1/pl not_active IP Right Cessation
- 2000-05-08 MX MXPA01012124A patent/MXPA01012124A/es active IP Right Grant
- 2000-05-08 KR KR10-2001-7015090A patent/KR100477782B1/ko not_active Expired - Fee Related
- 2000-05-08 AU AU41385/00A patent/AU777413B2/en not_active Ceased
- 2000-05-08 AT AT00920981T patent/ATE234097T1/de not_active IP Right Cessation
- 2000-05-08 HK HK02107882.4A patent/HK1046366B/zh not_active IP Right Cessation
- 2000-05-08 SK SK1678-2001A patent/SK284590B6/sk not_active IP Right Cessation
- 2000-05-08 IL IL14595000A patent/IL145950A0/xx active IP Right Grant
- 2000-05-08 SI SI200030060T patent/SI1181018T1/xx unknown
- 2000-05-08 HU HU0201297A patent/HUP0201297A3/hu unknown
- 2000-05-08 DE DE60001649T patent/DE60001649T2/de not_active Expired - Lifetime
- 2000-05-08 CZ CZ20014230A patent/CZ20014230A3/cs unknown
- 2000-05-08 DK DK00920981T patent/DK1181018T3/da active
- 2000-05-08 JP JP2000620959A patent/JP3942827B2/ja not_active Expired - Lifetime
- 2000-05-08 TR TR2001/03392T patent/TR200103392T2/xx unknown
- 2000-05-08 HR HR20010878A patent/HRP20010878B1/xx not_active IP Right Cessation
- 2000-05-08 GE GEAP20006213A patent/GEP20033113B/en unknown
- 2000-05-08 OA OA1200100304A patent/OA11946A/en unknown
- 2000-05-08 EP EP00920981A patent/EP1181018B1/fr not_active Expired - Lifetime
- 2000-05-10 HN HN2000000071A patent/HN2000000071A/es unknown
- 2000-05-19 PA PA20008495801A patent/PA8495801A1/es unknown
- 2000-05-22 PE PE2000000480A patent/PE20010127A1/es not_active Application Discontinuation
- 2000-05-23 TW TW089109949A patent/TWI263498B/zh active
- 2000-05-23 GC GCP2000670 patent/GC0000190A/en active
- 2000-05-24 MY MYPI20002273A patent/MY127891A/en unknown
- 2000-05-24 MA MA25991A patent/MA26741A1/fr unknown
- 2000-05-24 TN TNTNSN00112A patent/TNSN00112A1/fr unknown
- 2000-05-24 DZ DZ000093A patent/DZ3049A1/fr active
- 2000-05-24 CO CO00038317A patent/CO5170458A1/es not_active Application Discontinuation
- 2000-05-25 UY UY26166A patent/UY26166A1/es not_active Application Discontinuation
- 2000-05-25 GT GT200000081A patent/GT200000081A/es unknown
- 2000-05-26 AR ARP000102585A patent/AR022643A1/es active IP Right Grant
- 2000-05-26 SV SV2000000085A patent/SV2001000085A/es not_active Application Discontinuation
- 2000-08-05 UA UA2001118094A patent/UA59491C2/uk unknown
2001
- 2001-10-15 IL IL145950A patent/IL145950A/en unknown
- 2001-10-30 IS IS6134A patent/IS2396B/is unknown
- 2001-11-19 CU CU20010266A patent/CU23223B7/es not_active IP Right Cessation
- 2001-11-23 CR CR6506A patent/CR6506A/es not_active Application Discontinuation
- 2001-11-26 ZA ZA200109692A patent/ZA200109692B/en unknown
- 2001-11-26 NO NO20015755A patent/NO320296B1/no unknown
- 2001-11-26 BG BG106153A patent/BG65367B1/bg unknown

Also Published As

Publication number	Publication date
BR0010990A (pt)	2002-03-05
EE04704B1 (et)	2006-10-16
CN1352560A (zh)	2002-06-05
NO20015755D0 (no)	2001-11-26
EA003907B1 (ru)	2003-10-30
IL145950A0 (en)	2002-07-25
IL145950A (en)	2007-12-03
CR6506A (es)	2004-03-24
HUP0201297A3 (en)	2005-09-28
CO5170458A1 (es)	2002-06-27
AR022643A1 (es)	2002-09-04
SV2001000085A (es)	2001-11-08
TNSN00112A1 (fr)	2005-11-10
WO2000072847A1 (fr)	2000-12-07
SI1181018T1 (en)	2003-06-30
HK1046366B (zh)	2005-07-29
KR100477782B1 (ko)	2005-03-21
HN2000000071A (es)	2001-02-02
ES2191618T3 (es)	2003-09-16
EA200101131A1 (ru)	2002-04-25
HUP0201297A2 (en)	2002-08-28
CA2371550C (fr)	2007-01-02
NO20015755L (no)	2002-01-23
PL352826A1 (en)	2003-09-08
CA2371550A1 (fr)	2000-12-07
UA59491C2 (uk)	2003-09-15
PE20010127A1 (es)	2001-02-06
CZ20014230A3 (cs)	2002-08-14
NO320296B1 (no)	2005-11-21
MA26741A1 (fr)	2004-12-20
OA11946A (en)	2006-04-13
DZ3049A1 (fr)	2004-03-27
GT200000081A (es)	2001-11-16
AU4138500A (en)	2000-12-18
ZA200109692B (en)	2002-11-26
TWI263498B (en)	2006-10-11
IS6134A (is)	2001-10-30
MXPA01012124A (es)	2002-06-04
DE60001649D1 (de)	2003-04-17
BG65367B1 (bg)	2008-04-30
NZ514764A (en)	2004-04-30
GC0000190A (en)	2006-03-29
BG106153A (bg)	2002-06-28
HRP20010878B1 (en)	2007-03-31
AP1409A (en)	2005-06-13
PA8495801A1 (es)	2001-12-14
ATE234097T1 (de)	2003-03-15
GEP20033113B (en)	2003-11-25
IS2396B (is)	2008-08-15
CN1196486C (zh)	2005-04-13
JP2003500449A (ja)	2003-01-07
KR20020048307A (ko)	2002-06-22
DK1181018T3 (da)	2003-04-22
UY26166A1 (es)	2000-12-29
TR200103392T2 (tr)	2002-11-21
PL196867B1 (pl)	2008-02-29
EP1181018A1 (fr)	2002-02-27
EE200100633A (et)	2003-02-17
CU23223B7 (es)	2007-08-30
AP2001002346A0 (en)	2001-12-31
YU76701A (sh)	2005-07-19
HK1046366A1 (en)	2003-01-10
MY127891A (en)	2006-12-29
SK16782001A3 (sk)	2002-09-10
EP1181018B1 (fr)	2003-03-12
JP3942827B2 (ja)	2007-07-11
RS50089B (sr)	2009-01-22
DE60001649T2 (de)	2003-08-21
AU777413B2 (en)	2004-10-14
HRP20010878A2 (en)	2003-06-30

Publication	Publication Date	Title
SK284590B6 (sk)	2005-07-01	Suspenzia ziprasidonu
JP3465820B2 (ja)	2003-11-10	トロバフロキサシン経口懸濁剤
WO2017077436A1 (fr)	2017-05-11	Suspensions orales de givinostat physiquement et chimiquement stables
WO2009112800A1 (fr)	2009-09-17	Composition de losartan
US6368638B1 (en)	2002-04-09	Process of making an aqueous calcium carbonate suspension
US20070134323A1 (en)	2007-06-14	Ziprasidone suspension
CN117597108A (zh)	2024-02-23	包含氨基甲酸酯化合物的口服水性悬浮液制剂
WO2025027531A1 (fr)	2025-02-06	Formulation liquide orale d'apixaban
TR201907059A2 (tr)	2020-11-23	Tri̇azol bi̇leşi̇ği̇ i̇çeren kararli oral formülasyon ve üreti̇m yöntemi̇

Legal Events

Date	Code	Title	Description
2010-02-08	MM4A	Patent lapsed due to non-payment of maintenance fees	Effective date: 20090508